JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

JNJ

187.78

-1.14%↓

ABT

127.46

+1.47%↑

MDT

93.8

+0.26%↑

VEEV

292.87

-0.07%↓

A

146.15

-0.81%↓

Search

Savara Inc

Abierto

SectorSalud

4.41 3.28

Resumen

Variación precio

24h

Actual

Mínimo

4.27

Máximo

4.46

Métricas clave

By Trading Economics

Ingresos

-3.8M

-30M

Margen de beneficio

-10,677.941

Empleados

59

EBITDA

-1.9M

-30M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+111.19% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

244M

710M

Apertura anterior

1.13

Cierre anterior

4.41

Noticias sobre sentimiento de mercado

By Acuity

12%

88%

14 / 373 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Savara Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 oct 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

27 oct 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

27 oct 2025, 21:42 UTC

Ganancias

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

27 oct 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

27 oct 2025, 23:42 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

27 oct 2025, 23:37 UTC

Charlas de Mercado

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

27 oct 2025, 23:00 UTC

Ganancias

The Good Vibes Are Back on Wall Street -- WSJ

27 oct 2025, 22:45 UTC

Adquisiciones, fusiones, absorciones

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

27 oct 2025, 22:06 UTC

Charlas de Mercado
Ganancias

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

27 oct 2025, 22:05 UTC

Ganancias

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

27 oct 2025, 22:04 UTC

Ganancias

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct 2025, 22:04 UTC

Ganancias

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

27 oct 2025, 22:03 UTC

Ganancias

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

27 oct 2025, 21:27 UTC

Ganancias

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

27 oct 2025, 21:19 UTC

Ganancias

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

27 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

27 oct 2025, 20:37 UTC

Ganancias

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

27 oct 2025, 20:31 UTC

Ganancias

Nucor Sees 4Q Earnings Lower Than 3Q

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q EPS $2.63 >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Net $607M >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Sales $8.52B >NUE

27 oct 2025, 20:30 UTC

Ganancias

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Adj EPS $1.98 >WM

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Rev $6.44B >WM

27 oct 2025, 20:30 UTC

Ganancias

Waste Management 3Q Net $603M >WM

Comparación entre iguales

Cambio de precio

Savara Inc Esperado

Precio Objetivo

By TipRanks

111.19% repunte

Estimación a 12 meses

Media 9.25 USD  111.19%

Máximo 16 USD

Mínimo 2 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Savara Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

7

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.76 / 2.84Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

14 / 373 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat